Drugs / RAD140
RAD140
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03088527 | Oct 2017 → Aug 2020 | hormone receptor-positive breast cancer | Stemline Therapeutics, Inc. | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RAD140 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03088527 ↗ |
| Known as | Testolone | ChEMBL registry synonym — accepted as the source's own label CHEMBL1672635 ↗ |
| Known as | Vosilasarm | ChEMBL registry synonym — accepted as the source's own label CHEMBL1672635 ↗ |
| Modality | Small molecule | — CHEMBL1672635 ↗ |
| Route | Oral | “for oral administration” NCT03088527 ↗ |